Straits Times Index
3,307.90 -6.15 (-0.19%) S&P 500
5,313.42 +5.29 (+0.10%) Dow
39,845.81 +39.04 (+0.10%) Nasdaq
16,797.98 +3.11 (+0.02%) Bitcoin USD
70,272.86 +3,311.89 (+4.95%) CMC Crypto 200
1,534.03 +45.49 (+3.05%)
OCGN Jul 2024 1.500 put
| Previous close | 0.2000 |
| Open | 0.2400 |
| Bid | 0.2000 |
| Ask | 0.2500 |
| Strike | 1.50 |
| Expiry date | 2024-07-19 |
| Day's range | 0.2400 - 0.2500 |
| Contract range | N/A |
| Volume | |
| Open interest | 191 |
GlobeNewswireOcugen Announces CSO to Present on Modifier Gene Therapy at International Society for Cell & Gene Therapy 2024
MALVERN, Pa., May 20, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Arun Upadhyay, PhD, Chief Scientific Officer, Head of Research & Development, Ocugen will speak at the International Society for Cell & Gene Therapy (ISCT) Annual Meeting being held May 29-June 1, 2024 in Vancouver, Canada. “I’m very pleased to present OC
- GlobeNewswire
Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy
MALVERN, Pa., May 15, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that dosing is complete in the second cohort of its Phase 1/2 GARDian clinical trial for OCU410ST (AAV-hRORA)—a modifier gene therapy candidate being developed for Stargardt disease as a one-time treatment for life. "The completion of dosing for Cohort 2 p
- GuruFocus.com
Ocugen Inc (OCGN) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances Amid ...
Discover how Ocugen Inc navigates its financial landscape while pushing boundaries in gene therapy development.
